The instant disclosure provides antibodies that specifically bind to human CTLA-4 and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
van Dijk; Marc (Bosch en Duin, NL), Mundt; Cornelia Anne (Lorrach, DE), Ritter; Gerd (New York, NY), Schaer; David (Mamaroneck, NY), Wolchok; Jedd David (New York, NY), Merghoub; Taha (Jersey City, NJ), Savitsky; David Adam (Boxford, MA), Wilson; Nicholas Stuart (San Carlos, CA)
AGENUS INC. (Lexington, MA) LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (Zurich, CH) MEMORIAL SLOAN KETTERING CANCER CENTER (New York, NY)
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.